The FDA Drug Office Is Starting to Look Like the Story
Reuters reported May 15 that Tracey Beth Hoeg, acting head of the FDA’s Center for Drug Evaluation and Research, is expected to leave after only about five months in the job. CDER is one of the most important offices in American medicine because it oversees the review of prescription drugs. Reuters noted that Hoeg was the fifth person to run the center in 15 months during Trump’s second term.
The departure follows the reported exit of FDA Commissioner Marty Makary and comes after Hoeg drew attention for positions on vaccine policy and drug-safety disputes. Reuters reported that she had cast doubt on COVID vaccines during the pandemic, had considered label changes related to COVID vaccination for young men, had raised safety questions over RSV treatments from Merck, Sanofi and AstraZeneca, and had been involved in disagreement over Sanofi’s type 1 diabetes drug teplizumab.
The core issue is not one official’s résumé. It is institutional churn inside the agency that decides which medicines reach patients and on what evidence. A regulator can be too captured, too slow or too political. But constant leadership turnover is its own public-health risk because it weakens trust in process, accountability and scientific continuity.
The FDA story is not about whether one official should stay or go. It is about what happens when the institution that arbitrates medical trust starts looking unstable from the inside.
The Center for Drug Evaluation and Research is not a symbolic bureau. It is the part of the FDA that sits between pharmaceutical companies, clinical evidence, doctors and patients. When that office is steady, people can argue about its decisions on the merits. When leadership churn becomes the story, every decision starts to look like a proxy fight.
That is why Luke’s lens fits. This is not a narrow medical controversy. It is a state-capacity story. A country can have brilliant researchers, powerful drug companies, major hospitals and world-class universities, yet still lose public trust if the referee looks politicized, erratic or captured.
Reuters’ details matter because they show the pressure points. COVID vaccine labeling, RSV treatments and diabetes-drug disputes are not abstract culture-war subjects. They involve evidence, risk tolerance, patient access, company incentives and public communication. Reasonable people can disagree about where a regulator should draw lines. But they need to believe there is a line-drawing process that survives personalities.
Leadership instability makes that harder. If CDER has five leaders in 15 months, the public is left asking whether policy is being made by evidence, by ideology, by industry pressure, by political loyalty, or by whoever happens to be holding the chair that week. That ambiguity is corrosive.
The old public-health bargain was simple: citizens would accept complicated expert decisions because the institutions had earned some baseline trust. That bargain is now damaged. Some of the damage came from bureaucratic arrogance. Some came from genuine policy mistakes. Some came from media overreach. Some came from political actors who realized that institutional mistrust could be harvested for power.
The answer is not to pretend the FDA is above criticism. It is not. Drug regulation has always involved tradeoffs, lobbying and imperfect information. But if reform becomes permanent turbulence, the cure can become another disease. Patients do not benefit when every review looks like an ideological ambush. Doctors do not benefit when guidance feels unstable. Companies do not benefit when the rules look arbitrary. Taxpayers do not benefit when the agency loses credibility and then asks the public to trust it in the next emergency.
The country needs a tougher FDA, not a theatrical FDA. Tough means transparent evidence standards, clear explanations, visible conflict-of-interest rules, serious post-market surveillance and the humility to correct errors. It does not mean converting every drug decision into another trench in the culture war.
The churn at CDER is a warning. Public trust is not restored by swapping one faction’s experts for another faction’s experts. It is restored by making the process legible enough that people can disagree without assuming the game is rigged.